Company Description
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States.
Its lead product is ONP-002, for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification.
The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Products.
It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Janet Huffman |
Contact Details
Address: 4902 Eisenhower Boulevard, Suite 125 Tampa, Florida 33634 United States | |
| Phone | 813 286 7900 |
| Website | oragenics.com |
Stock Details
| Ticker Symbol | OGEN |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001174940 |
| CUSIP Number | 684023500 |
| ISIN Number | US6840235005 |
| Employer ID | 59-3410522 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Janet Huffman | Interim Chief Executive Officer, President, Chief Financial Officer, Secretary and Treasurer |
| Charles L. Pope CPA | Executive Chairman |
| Greg Gironda | Head of Business Development |
| Dr. James P. Kelly M.A., M.D. | Chief Medical Officer |
| Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D. | Chief Clinical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2025 | 8-K | Current Report |
| Apr 1, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 19, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 14, 2025 | 10-K | Annual Report |
| Mar 6, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 5, 2025 | 8-K | Current Report |
| Feb 4, 2025 | RW | Filing |